1. Moscow regional scientific and clinical research Institute named after M. F. Vladimirsky (Moscow, Russian Federation)

Keywords: acromegaly, gastrointestinal tract, neoplasms, colon polyps, colon diverticula

Abstract:Acromegaly is a severe neuroendocrine disease caused by increased production of somatotropic hormone by adenohypophysis tumor. The somatotropic hormone is indirectly, via insulin-like growth factor-1, acts on all organs and systems of the body, causing a large number of complications, including those of the gastrointestinal tract. Numerous cases of diagnosing both benign and malignant neoplasms have been described in the literature in this group of patients. About 15% of patients with acromegaly die from cancer, especially colon cancer, which frequency varies from 2 to 14 times the increase in comparison with the general population. However, there is an extremely low amount of studies of the upper part of the digestive tract in patients with acromegaly. The article reflects the results of various domestic and foreign studies on the upper and lower divisions of the gastrointestinal tract of patients with acromegaly, malignant and benign neoplasms of the stomach and colon, diverticular disease in patients with acromegaly, as well as possible prerequisites for their development, based on the pathogenesis of the underlying disease.

• References total 36 ⇓ :: .
  1. Beauregard C., Truong U., Hardy J. et al. Long- term outcome and mortality after transsphenoidal adenomectomy for acromegaly // J. Clin. Endocrinol.-2003. - Vol.58. - P. 86-91
  2. Gibney J., Healy M., Sonksen P. The growth hormone/insulin-like growth factor-1 axis in exercise and sport // J. Endocr. Rev. - 2007. - Vol. - 28. - P. 603-624.
  3. Melmed S., Casanueva F., Cavagnini F. et al. Consensus statement: medical management of acromegaly // Eur. J. Endocrinol. - 2005. - Vol.153. - P. 737-740.
  4. Arosio M, Reimondo G, Malchiodi E, et. al. Italian Study Group of Acromegaly. Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol. 2012;167(2):189-98. doi: 10.1530/EJE-12-0084
  5. Sherlock M, Ayuk J, Tomlinson J.W, et.al. Mortality in patients with pituitary disease. Endocr Rev. 2010;31(3):301-42.doi: 10.1210/er.2009-0033.
  6. Wright A.D, Hill D.M, Lowy C, Fraser T.R. Mortality in acromegaly. Q J Med. 1970;39(153):1-16.
  7. Loeper S, Ezzat S. Acromegaly: re-thinking the cancer risk. Rev Endocr Metab Disord. 2008;9(1):41-58. doi: 10.1007/s11154-007-9063-z.
  8. Nabarro J.D. Acromegaly. Clin Endocrinol (Oxf).1987;26(4):481-512. doi: 10.1111/j.1365-2265.1987.tb00805.x.
  9. Bengtsson B.A, Edén S, Ernest I, et.al. Epidemiology and long-term survival in acromegaly. A study of 166 cases di agnosed between 1955 and 1984. Acta Med Scand. 1988;223(4):327-35. doi: 10.1111/j.0954-6820.1988.tb15881.x.
  10. Etxabe J, Gaztambide P, Latorre P, Vazquez J.A. Acromegaly: an epidemilogical study. J Endocrinol Invest. 1993;16(3):181-7. doi: 10.1007/BF03344942.
  11. Bates A.S, Van’t Hoff W, Jones J.M, Clayton R.N. An audit of outcome of treatment in acromegaly. Q J Med. 1993;86(5):293-9. doi: http://dx.doi.org/293-299.
  12. Rajasoorya C, Holdaway I.M, Wrightson P, et.al. Determinants of clinical outcome and survivial in acromegaly. Clin Endocrinol (Oxf). 1994;41(1):95-102. doi:10.1111/j.1365-2265.1994.tb03789.x
  13. Melmed S.M. J Clin Endocrinol Metabol 2001; 86: 2929-2934; Mestrón A., Webb S. M. In: Endocrine Society. San Francisco 2002; abstract AACE Acromegaly Guidelines Task Force, AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly.// Endocr. Pract. 2011; 10(3): 213-25
  14. Dedov I. I., Molitvoslovova N. N., Rozhinskaya L. YA., Mel’nichenko G. A. Federal’nye klinicheskie rekomendacii po klinike, diagnostike, differencial’noj diagnostike i metodam lecheniya akromegalii.// Problemy ehndokrinologii. 2013. T. 59, N6. S. 4–18
  15. Baldvinsdottir T., Jonasson J. G., Thorsson A. V. Epidemiology of pituitary tumorous in Iceland 1955-2007: a Nationwide study. 10th European Congress of Endocrinology, 3-7 May, Berlin, Germany. Endocrine Abstracts 2008; 16: 315.
  16. Bates A.S., Vant Hoff W., Jones J. M. Does treatment of acromegaly affect life expectancy? Metabolism 1995; 44: Suppl 1: 1-5
  17. Baris D, Gridley G, Ron E, et al. Jr. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control. 2002;13(5):395-400. doi:10.1023/A:1015713732717
  18. Brunner J.E, Johnson C.C, Zafar S, et.al. Colon cancer and polyps in acromegaly: increased risk associated with family history of colon cancer. Clin Endocrinol (Oxf). 1990;32(1):65-71. doi: 10.1111/j.1365-2265.1990.tb03751.x.
  19. Mustacchi P, Shimkin M.B. Occurrence of cancer in acromegaly and in hypopituitarism.Cancer. 1957;10(1):100-4. doi: 10.1002/1097-0 1 4 2 (1 9 5 7 0 1 / 0 2) 1 0: 1 № 1 0 0:: A I D - C N -CR2820100113>3.0.CO;2-V
  20. Klein I, Parveen G, Gavaler J.S, Vanthiel D.H. Colonic polyps in patients with acromegaly. Ann Intern Med. 1982;97(1):27-30. doi:10.7326/0003-4819-97-1-27
  21. Ron E, Gridley G, Hrubec Z, et al. Jr. Acromegaly and gastrointestinal cancer. Cancer. 1991;68(8):1673-7.doi: 10.1002/1097-0142(19911015)68:8<1673: AID-CNCR2820680802>3.0.CO;2-0
  22. Kurimoto M, Fukuda I, Hizuka N, Takano K. The prevalence of benign and malignant tumors in patients with acromegaly at a single institute. Endocr J. 2008;55(1):67-71. doi: http://doi.org/10.1507/endocrj.K07E-010
  23. Rokkas T, Pistiolas D, Sechopoulos P, et al. Risk of colorectal neoplasm 42 in patients with acromegaly: a meta-analysis. World J Gastroenterol. 2008; 14: 3484-3489.
  24. Attanasio R, Mainolfi A, Grimaldi F, et al. Somatostatin analogs and 43 gallstones: a retrospective survey on a large series of acromegalic patients. J Endocrinol Invest. 2008; 31: 704-710.
  25. Cheng S., Gomez K., Serri O., et al. The role of diabetes in acromegaly associated neoplasia. PLoS One. 2015 May 21;10(5): e0127276. doi: 10.1371/journal.pone.0127276.eCollection 2015
  26. Bolfi F., Miot H. A., Resende M., et al. Frequency of various types of neoplasia in a group of acromegalic patients. Arq Bras Endocrinol Metabol. 2013 Nov;57(8):612-6.
  27. Kato K., Takeshita Y., Misu H., et al. Duodenal adenocarcinoma with neuroendocrine features in a patient with acromegaly and thyroid papillary adenocarcinoma: a unique combination of endocrine neoplasia. Endocr J. 2012;59(9):791-6. Epub 2012 May 31.
  28. Dworakowska D., Gueorguiev M., Kelly P., et al. Repeated colonoscopic screening of patients with acromegaly: 15-year experience identifies those at risk of new colonic neoplasia and allows for effective screening guidelines. Eur J Endocrinol 2010; 163: 1: 21-28.
  29. Oleynik OV, Molitvoslovova NN. Potential predictors and frequency of detection of thyroid and gastrointestinal tumors in patients with acromegaly. Problems of endocrinology. 2015;61 (2):4–7. doi:10.14341/probl20156124–7
  30. Wassenaar M.J, Cazemier M, Biermasz N.R, et al. Acromegaly is associated with an increased prevalence of colonic diverticula: a case-control study.// J Clin Endocrinol Metab, 2010, 95 (5): 2073-2079
  31. Baserga R, Prisco M, Hongo A. IGFs and cell growth. In: Roberts C.T, Rosenfeld R.G, eds. The IGF system. Molecular biology, physiology, and clinical applications. Totowa, NJ: Humana Press;1999, 329-353
  32. LeRoith D, Werner H, Beitner-Johnson D, Roberts Jr C.T. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev.1995.143-163
  33. LeRoith D. Regulation of proliferation and apoptosis by the insulin-like growth factor I receptor. Growth Horm IGF Res.2000, 1:12-13
  34. Ng S.T, Zhou J, Adesanya O.O, Wang J, et al. Growth hormone treatment induces mammary gland hyperplasia in aging primates.Nat Med. 1997, 3:1141-1144
  35. Colao A, Ferone D, Marzullo P, et. al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management.// Endocr Rev 2004 25: 102-152
  36. Dutta P, Bhansali A, Vaiphei K, et al // Colonic neoplasia in acromegaly: increased proliferation or decreased apoptosis? Pituitary. 2012 Jun;15 (2):166-73

Full text is published :
Titaeva A. A., Belousova E. A., Tereshchenko S. G. BENIGN AND MALIGNANT NEOPLASMS OF THE GASTROINTESTINAL TRACT IN PATIENTS WITH ACROMEGALY. Experimental and Clinical Gastroenterology Journal. 2018;154(06):94-97
Read & Download full text

1. Public budgetary educational institution of higher education «Ogarev Mordovia State University» of Ministry of Education of Russia (Saransk, Russian Federation)

Keywords: mechanical jaundice, Remaxol, reparative regeneration, oxidative stress, hypoxia, endogenous intoxication

Abstract:Goal. To study the effects of complex therapy with Remaksol on the reparative process of a laparotomic wound in the early postoperative period in patients with mechanical jaundice. Material and methods of investigation. We performed clinical and laboratory studies in 40 patients with mechanical jaundice of a non-tumoral nature, 22 patients received Remaxol in their early postoperative period (daily intravenous infusion of 400.0 ml for 5 days). The control group consisted of 18 patients with chronic calculous cholecystitis. Patients underwent cholecystectomy, choledochotomy with choledocholithoextraction or the formation of choledochoduodenoanastomosis. Results. Under mechanical jaundice the reparative potential of tissues is significantly reduced. One of the most important mechanisms of inhibition of tissue regeneration is the deterioration of their bioenergetics. Membrane destabilizing phenomena of regenerating structures are also of great importance due to excessive activity of peroxide oxidation of membrane lipids and activation of phospholipases. Negative factors, aggravating regeneration, in patients were hypoxia, endotoxemia and hypoalbuminemia. Application in the early postoperative period in the complex therapy of Remaxol leads to a significant correction of factors detrimental to the reparative process, which is responsible for the improvement of tissue healing in conditions of cholestasis. Correction of endogenous intoxication and hypoalbuminemia is associated with the hepatoprotective effect of the drug. Conclusion. The Remaxol use increases the reparative potential of laparotomic wounds in patients with mechanical jaundice.

• References total 7 ⇓ :: .
  1. Vinnik YuS, Pakhomova RA, Kochetova LV, Voronova EA, Kozlov VV, Kirichenko AK. Predictors of hepatic insufficiency in obstructive jaundice. Khirurgiya. Zhurnal imeni N. I. Pirogova. 2018;(3):37–41. https://doi.org/10.17116/hirurgia2018337–41
  2. Pakhomova R. A., Kochetova L. V. Clinical implications Ns of the mechanical icterus and liver failure Depending on severity of the mechanical icterus of the good – Quality genesis. Modern problems of science and education. 2017. no.6, р. 47
  3. Bolevich SB, Stupin VA, Gakhramanov TV, Khokonov MA, Silina EV, Men’shova NI, Bogdanova LS. Free radical processes at patients with pathologies of biliary ducts and methods of their correction. Khirurgiya. Zhurnal imeni N. I. Pirogova. 2010;(7):65–70.
  4. Silina E. V., Stupin V. A., Gakhramanov T. V., Khokonov M. A., Bolevich S. B., Men’shova N.I., Sinelnikova T. G. Oxidative stress in patients with mechanical jaundice of different origin and severity. Clinical Medicine. 2011;89(3):57–63
  5. Khilko S. S., Butyrskii A. G. About biochemical parameters in experimental obstructive jaundice and the ways of their correction. Tavricheskiy Mediko-Biologicheskiy Vestnik. 2017;20(2):134–139.
  6. Vinogradova T. I., Sukhanov D. S., Zabolotnykh N. V., Kovalenko A. L., Vasil’eva S. N., Romantsov M. G. Comparative study of remaxol and ademethionine effects on reparative regeneration processes in liver under surgical invasion conditions. Experimental and Clinical Pharmacology. 2011;74(2):34–38. https://doi.org/10.30906/0869–2092–2011–74–2–34–38
  7. Sukhanov D. S., Vinogradova T. I., Zabolotnyh N. V., Vitovskaya M. L., Momot D. S., Elkin A. V. The pharmacological activity of succinatecontaining hepatoprotectors in experimental liver damage. Scientific medical bulletin of Yugra. 2014;1–2(5–6):189–192

Full text is published :
Vlasov A. P., Zaitsev P. P., Vlasova T. I., Grigoriev A. G. et al. OPTIMIZATION OF A LAPAROTOMIC WOUND REPARATIVE REGENERATION UNDER MECHANICAL JAUNDICE. Experimental and Clinical Gastroenterology Journal. 2018;154(06):98-104
Read & Download full text

1. M. Sechenov first Moscow state medical University (Moscow, Russian Federation)

Keywords: H. Pylori, iron deficiency, anemia

Abstract:The article analyzes the results of recent studies on the relationship of iron deficiency, iron deficiency anemia and H. Pylori infection. The results of recent epidemiological studies of the combination of these diseases and the proposed theory of the pathogenesis of iron deficiency in infection with HP, including the role of chronic inflammation supported by HP in the formation of anemia of chronic diseases.

• References total 75 ⇓ :: .
  1. Feeding and nutrition of infants and young children. Guidelines for the WHO European Region, with emphasis on the former Soviet countries. WHO Regional Publications, European Series, 87. WHO 2000, updated reprint 2003.
  2. Epidemiology of iron deficiency anaemia in four European countries: a population-based study in primary care // Eur J Haematol. 2016; 97(6):583–593
  3. Xia, W., Zhang, X., Wang, J., Sun, C. & Wu, L. Survey of anaemia and Helicobacter pylori infection in adolescent girls in Suihua, China and enhancement of iron intervention effects by H. pylori eradication. Br J Nutr 108, 357–362 (2012).
  4. Hu, Y. et al. Study on the anemia status of Chinese urban residents in 2010–2012. Chin J Prev Med 50, 213–216 (2016).
  5. Muhsen, K. & Cohen, D. Helicobacter pylori Infection and Anemia. Am J Trop Med Hyg 89, 398–398 (2013). Muhsen, K. & Cohen, D. Helicobacter pylori Infection and Anemia. Am J Trop Med Hyg 89, 398–398 (2013).
  6. Mei-Yan Xu, Bing Cao, Bao-Shi Yuan, Jian Yin1, Lan Liu & Qing-Bin Lu / Association of anaemia with Helicobacter pylori infection: a retrospective study // Scientific REPORTS |7: 13434 wwww.nature.com/scientific reports
  7. Choe YH, Kim SK, Hong YC. The relationship between Helicobacter pylori infection and iron deficiency: seroprevalence study in 937 pubescent children. Arch Dis Child 2003; 88:178; PMID:12538339; http://dx.doi.org/ 10.1136/adc.88.2.178-a
  8. Yang YJ, Sheu BS, Lee SC, Yang HB, Wu JJ. Children of Helicobacter pylori-infected dyspeptic mothers are predisposed to H. pylori acquisition with subsequent iron deficiency and growth retardation. Helicobacter 2005; 10:249–55; PMID:15904483; http://dx.doi.org/10.1111/j.1523–5378.2005.00317.x
  9. Baggett HC, Parkinson AJ, Muth PT, Gold BD, Gessner BD. Endemic iron deficiency associated with Helicobacter pylori infection among schoolaged children in Alaska. Pediatrics 2006; 117: e396–404; PMID:16452320; http://dx.doi.org/10.1542/ peds.2005– 1129
  10. Cardenas VM, Mulla ZD, Ortiz M, Graham DY. Iron deficiency and Helicobacter pylori infection in the United States. Am J Epidemiol 2006; 163:127–34; PMID:16306309; http://dx.doi.org/10.1093/aje/ kwj018
  11. Muhsen K, Barak M, Henig C, Alpert G, Ornoy A, Cohen D. Is the association between Helicobacter pylori infection and anemia age dependent? Helicobacter 2010; 15:467–72; PMID:21083753; http://dx.doi. org/10.1111/j.1523– 5378.2010.00793.x
  12. Afifi RAR, Ali DK, Shaheen IAM. A localized casecontrol study of extra-gastric manifestations of Helicobacter pylori infection in children. Indian J Pediatr 2011; 78:418–22; PMID:21165719; http:// dx.doi.org/1 0.1007/ s12098–010– 0308–6
  13. Queiroz DMM, Harris PR, Sanderson IR, Windle HJ, Walker MM, Rocha AMC, Rocha GA, Carvalho SD, Bittencourt PF, de Castro LP, et al. Iron status and Helicobacter pylori infection in symptomatic children: an international multi-centered study. PLoS One 2013; 8: e68833; PMID:23861946; http://dx.doi. org/10.1371/journal.pone.0068833
  14. Soglu OD, Gцkзe S, Saglam AT, Sцkьcь S, Saner G. Association of Helicobacter pylori infection with gastroduodenal disease, epidemiologic factors and iron-deficiency anemia in Turkish children undergoing endoscopy, and impact on growth. Pediatr Int 2007; 49:858–63; PMID:18045286; http://dx.doi. org/10.1111/j.1442–200X.2007.02444.x
  15. Berg G, Bode G, Blettner M, Boeing H, Brenner H. Helicobacter pylori infection and serum ferritin: A population-based study among 1806 adults in Germany. Am J Gastroenterol. 2001 Apr; 96(4):1014–1018.
  16. Milman N, Rosenstock S, Andersen L, Jorgensen T, Bonnevie O. Serum ferritin, hemoglobin, and Helicobacter pylori infection: a seroepidemiologic survey comprising 2794 Danish adults. Gastroenterology. 1998 Aug; 115(2):268–274.
  17. Yuan W, Li Y, Yang K, Ma B, Guan Q, Wang D, et al. Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials. Scand J Gastroenterol. 2010 Jun; 45(6):665–676.
  18. Qu XH, Huang XL, Xiong P, Zhu CY, Huang YL, Lu LG, et al. Does Helicobacter pylori infection play a role in iron deficiency anemia? A meta-analysis. World J Gastroenterol. 2010 Feb 21; 16(7):886–896.
  19. Huang X, Qu X, Yan W, Huang Y, Cai M, Hu B, et al. Iron deficiency anaemia can be improved after eradication of Helicobacter pylori. Postgrad Med J. 2010 May; 86(1015):272–278.
  20. Zhang ZF, Yang N, Zhao G, Zhu L, Zhu Y, Wang LX. Effect of Helicobacter pylori eradication on iron deficiency. Chinese medical journal. 2010 Jul; 123(14):1924–1930.
  21. Y. H. Choe, J. E. Lee, and S. K. Kim, “Effect of Helicobacter pylori eradication on sideropenic refractory anaemia in adolescent girls with Helicobacter pylori infection,” Acta Paediatrica, International Journal of Paediatrics, vol. 89, no. 2, pp. 154–157, 2000.
  22. T. Sugiyama, M. Tsuchida, K. Yokota, M. Shimodan, and M. Asaka, “Improvement of long-standing iron-deficiency anemia in adults after eradication of Helicobacter pylori infection,” Internal Medicine, vol. 41, no. 6, pp. 491–494, 2002.
  23. D. Mahalanabis, M. A. Islam, S. Shaikh et al., “Haematological response to iron supplementation is reduced in children with asymptomatic Helicobacter pylori infection,” British Journal of Nutrition, vol. 94, no. 6, pp. 969–975, 2005.
  24. C. Ciacci, F. Sabbatini, R. Cavallaro et al., “Helicobacter pylori impairs iron absorption in infected individuals,” Digestive and Liver Disease, vol. 36, no. 7, pp. 455– 460, 2004.
  25. Duclaux-Loras R, Lachaux A. [Helicobacter pylori infection, a classic but often unrecognized cause of iron deficiency anemia in teenagers]. Arch Pediatr 2013;20(4):395–7.
  26. Yip, R. et al. Pervasive occult gastrointestinal bleeding in an Alaska native population with prevalent iron deficiency – Role of Helicobacter pylori gastritis. JAMA 277, 1135–1139 (1997).
  27. Blecker U, Renders F, Lanciers S, Vandenplas Y. Syncopes leading to the diagnosis of a Helicobacter pylori positive chronic active haemorrhagic gastritis. Eur J Pediatr 1991; 150:560–1; http://dx.doi.org/10.1007/BF02072207
  28. Rockey, D. C. & Cello, J. P. Evaluation of the Gastrointestinal-Tract in Patients with Iron-Deficiency Anemia. N Engl J Med 329, 1691–1695 (1993).
  29. Mubarak, N., Gasim, G. I., Khalafalla, K. E., Ali, N. I. & Adam, I. Helicobacter pylori, anemia, iron deficiency and thrombocytopenia among pregnant women at Khartoum, Sudan. Trans R Soc Trop Med Hyg 108, 380–384 (2014).
  30. Otto, B. R., Verweijvanvught, A. M. J. J. & Maclaren, D. M. Transferrins and Heme-Compounds as Iron Sources for Pathogenic Bacteria. Critical Reviews in Microbiology 18, 217–233 (1992).
  31. Andrews SC, Robinson AK, Rodriguez- Quinones F. Bacterial iron homeostasis. FEMS Microbiol Rev. 2003; 27: 215±237.
  32. Choe YH, Hwang TS, Kim HJ, Shin SH, Song SU, Choi MS. A possible relation of the Helicobacter pylori pfr gene to iron deficiency anemia? Helicobacter. 2001; 6: 55±59.
  33. Jeon BH, Oh YJ, Lee NG, Choe YH. Polymorphism of the Helicobacter pylori feoB gene in Korea: a possible relation with iron-deficiency anemia? Helicobacter. 2004; 9: 330±334. https://doi.org/10.1111/j. 1083–4389.2004.00239.x
  34. Muhsen K, Barak M, Shifnaidel L, Nir A, Bassal R, Cohen D. Helicobacter pylori infection is associated with low serum ferritin levels in Israeli Arab children: a seroepidemiologic study. J Pediatr Gastroenterol Nutr 2009; 49: 262– 264.
  35. Annibale B, Capurso G, Lahner E, Passi S, Ricci R, Maggio F, Delle Fave G. Concomitant alterations in intragastric pH and ascorbic acid concentration in patients with Helicobacter pylori gastritis and associated iron deficiency anaemia. Gut 2003; 52: 496–501.
  36. Choi JW. Serum-soluble transferrin receptor concentrations in Helicobacter pylori-associated iron- deficiency anemia. Ann Hematol 2006; 85: 735–737.
  37. Bini EJ. Helicobacter pylori and iron deficiency anemia: guilty as charged? Am J Med 2001; 111: 495–497. Kaptan K, Beyan C, Ugur U, et al. Helicobacter pylori – it is a novel causative agent in vitamin B12 deficiency? Arch Intern Med 2000;160:1349–53.
  38. Kuipers EJ, Perez-Perez GI, Meuwissen SG, Blaser MJ. Helicobacter pylori and atrophic gastritis: importance of the cagA status. J Natl Cancer Inst. 1995 Dec 6; 87(23):1777–1780. Wen S, Moss SF. Helicobacter pylori virulence factors in gastric carcinogenesis. Cancer Lett. 2009 Sep 8; 282(1):1–8.
  39. Anderson LA, Murphy SJ, Johnston BT, Watson RG, Ferguson HR, Bamford KB, et al. Relationship between Helicobacter pylori infection and gastric atrophy and the stages of the oesophageal inflammation, metaplasia, adenocarcinoma sequence: results from the FINBAR case-control study. Gut. 2008 Jun; 57(6):734– 739.
  40. Cardenas VM, Prieto-Jimenez CA, Mulla ZD, Rivera JO, Dominguez DC, Graham DY, et al. Helicobacter pylori eradication and change in markers of iron stores among non-iron- deficient children in El Paso, Texas: an etiologic intervention study. J Pediatr Gastroenterol Nutr. 2011 Mar; 52(3):326–332.
  41. Muhsen K, Barak M, Shifnaidel L, Nir A, Bassal R, Cohen D. Helicobacter pylori infection is associated with low serum ferritin levels in Israeli Arab children: a seroepidemiologic study. J Pediatr Gastroenterol Nutr. 2009 Aug; 49 (2):262–264.
  42. Prentice A M Clinical Implications of New Insights into Hepcidin-Mediated Regulation of Iron Absorption and Metabolism Ann Nutr Metab. 2017;71 Suppl 3:40–48. doi:10.1159/000480743. Epub 2017 Dec 22.
  43. Girelli D, Ugolini S, Busti F, Marchi G, Castagna A. Modern iron replacement therapy: clinical and pathophysiological insights Int J Hematol. 2018 Jan;107(1):16–30. doi: 10.1007/s12185–017–2373–3. Epub 2017 Dec 1.
  44. Park C.H., Valore E. V., Waring A. J. et al. Hepcidin: a urinary antibacterial peptide synthesized in the liver. J. Biol. Chem.2001; 276: 7806–7810.
  45. Hunter H.N., Fulton D. B., Vogel H. J. The solution structure of human hepcidin, a antibicrobial activity that is involved in iron uptake and hereditary hemochromatosis. J. Biol. Chem. 2002; 277: 37597–37603.
  46. Kanda J, Mizumoto C, Kawabata H, Tsuchida H, Tomosugi N, Matsuo K, Uchiyama T. Serum hepcidin level and erythropoietic activity after hematopoietic stem cell transplantation. Haematologica. 2008; 93: 1550‐1554. Darshan D, Anderson GJ. Interacting signals in the control of hepcidin expression. Biometals. 2009; 22: 77 ‐87.
  47. Guo P, Cui R, Chang YZ, Wu WS, Qian ZM, Yoshida K, Qiao YT, Takeda S, Duan XL. Hepcidin, an antimicrobial peptide is downregulated in ceruloplasmin‐deficient mice. Peptides. 2009; 30: 262‐266.
  48. Hoppe M, Lönnerdal B, Hossain B, Olsson S, Nilsson F, Lundberg P A, Rödjer S, Hulthén L. Hepcidin, interleukin‐6 and hematological iron markers in males before and after heart surgery. J Nutr Biochem. 2009; 20: 11‐16.
  49. Bansal SS, Halket JM, Bomford A, Simpson RJ, Vasavda N, Thein SL, Hider RC. Quantitation of hepcidin in human urine by liquid chromatography‐mass spectrometry. Anal Biochem. 2009; 384: 245‐253.
  50. Fleming RE. Iron and inflammation: cross‐ talk between pathways regulating hepcidin. J Mol Med. 2008; 86: 491‐ 494.
  51. Oliveras‐Verge’s A, Espel‐Masferrer E. Elevated basal hepcidin levels in the liver may inhibit the development of malaria infection: Another piece towards solving the malaria puzzle? Med Hypotheses. 2008; 70: 630‐634.
  52. Christiansen H, Saile B, Hermann RM, Rave‐ Fränk M, Hille A, Schmidberger H, Hess CF, Ramadori G. Cancer Res Clin Oncol. 2007; 133: 297‐304.
  53. Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M: Hepcidin, an acute‐phase protein and a marker of inflammation in kidney transplant recipients with and without coronary artery disease. Transplant Proc. 2006; 38: 2895‐2898.
  54. Politou M, Papanikolaou G: Hepcidin: A key iron regulator involved in the pathogenesis of anaemia of chronic disease. Haema. 2004; 7: 165‐174.
  55. Swinkels DW, Drenth JPH. Hepcidin in the management of patients with mild non‐hemochromatotic iron overload: Fact or fiction? J Hepatol. 2008; 49: 680‐685.
  56. Ruivard M, Lainé F, Ganz T, Olbina G, Westerman M, Nemeth E, Rambeau M, Mazur A, Gerbaud L, Tournilhac V, Abergel A, Philippe P, Deugnier Y, Coudray C. Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin. J Hepatol. 2009; 50: 1219‐1225.
  57. CamaschellaC, SilvestriL. New and old playersinthe hepcidin pathway. Haematologica.2008;93:1441‐1444. Swinkels DW, Wetzels JFM. Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease? Nephrol Dial Transplant. 2008; 23: 2450‐2453.
  58. Fujita N, Sugimoto R, Motonishi S, Tomosugi N, Tanaka H, Takeo M, Iwasa M, Kobayashi Y, Hayashi H, Kaito M, Takei Y. Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. J Hepatol. 2008; 49: 702‐710.
  59. Oğuz A, Uzunlulu M, Hekim N. Hepcidin is not a marker of chronic inflammation in atherosclerosis. Anadolu Kardiyol Derg. 2006; 6: 239‐242.
  60. Arruda SF, de Almeida Siqueira EM, de Valência FF. Vitamin A deficiency increases hepcidin expression and oxidative stress in rat. Nutrition. 2009; 25: 472‐478.
  61. Kemna EH, Tjalsma H, Willems HL, Swinkels DW. Hepcidin: from discovery to differential diagnosis. Haematologica. 2008; 93: 90‐97.
  62. Chiang TH, Chiu SY, Chen SL, Yen AM, Fann JC, Liu CY, Chou CK, Chiu HM, Shun CT, Wu MS, Lin JT, Lee YC, Chen TH, Lin MW Serum Pepsinogen as a Predictor for Gastric Cancer Death: A 16 -Year Community-based Cohort Study. J Clin Gastroenterol. 2018 Jan 23. doi: 10.1097/MCG.0000000000000992.
  63. Burns M, Amaya A, Bodi C, Ge Z, Bakthavatchalu V, Ennis K, Wang TC, Georgieff M, Fox JG. Helicobacter pylori infection and low dietary iron alter behavior, induce iron deficiency anemia, and modulate hippocampal gene expression in female C57BL/6 mice. 2017 Mar 29;12(3): e0173108. doi: 10.1371/journal.pone.0173108. eCollection 2017.
  64. Siddique O, Ovalle A, Siddique AS, Moss SF. Helicobacter Pylori Infection: an Update for the Internist in the Age of Increasing Global Antibiotic Resistance. Am J Med. 2018 Jan 15. pii: S0002–9343(18)30013–5. doi: 10.1016/j.amjmed.2017.12.024.
  65. Schwarz P1, Kübler JA, Strnad P, Müller K, Barth TF, Gerloff A, Feick P, Peyssonnaux C, Vaulont S, Adler G, Kulaksiz H Hepcidin is localised in gastric parietal cells, regulates acid secretion and is induced by Helicobacter pylori infection. Gut. 2012 Feb;61(2):193–201. doi: 10.1136/gut.2011.241208. Epub 2011 Jul 13.
  66. Lee SY, Song EY, Yun YM, Yoon SY, Cho YH, Kim SY, et al. Serum prohepcidin levels in Helicobacter pylori infected patients with iron deficiency anemia. Korean J Intern Med 2010;25: 195e200.
  67. Azab SF, Esh AM. Serum hepcidin levels in Helicobacter pyloriinfected children with iron-deficiency anemia: a case-control study. Ann Hematol 2013;92:1477e83.
  68. Sato Y, Yoneyama O, Azumaya M, Takeuchi M, Sasaki SY, Yokoyama J, et al. The relationship between iron deficiency inpatients with Helicobacter pylori-infected nodular gastritis and the serum prohepcidin level. Helicobacter 2015;20:11e8.
  69. Ozkasap S, Yarali N, Isik P, Bay A, Kara A, Tunc B. The role of prohepcidin in anemia due to Helicobacter pylori infection. Pediatr Hematol Oncol 2013;30:425e31.
  70. Queiroz DMM, Rocha AMC, Melo FF, Rocha GA, Teixeira KN, Carvalho SD, Bittencourt PF, Castro LP, Crabtree JE. Increased gastric IL-1β concentration and iron deficiency parameters in H. pylori infected chil- dren. PLoS One 2013; 8: e57420; http://dx.doi.org/10.1371/journal.pone.0057420
  71. Inamura J, Ikuta K, Jimbo J, Shindo M, Sato K, Torimoto Y, Kohgo Y. Upregulation of hepcidin by interleukin- 1β in human hepatoma cell lines. Hepatol Res 2005; 33:198–205; http:// dx.doi.org/10.1016/j.hepres.2005.08.005
  72. Lee P, Peng H, Gelbart T, Wang L, Beutler E. Regulation of hepcidin transcription by interleu- kin-1 and interleukin-6. Proc Natl Acad Sci U S A 2005; 102:1906–10;; http://dx.doi. org/10.1073/pnas.0409808102
  73. Szu-Ta Chen, Yen-Hsuan Ni, Chuan-Chun Li, Shing-Hwa Liu / Hepcidin correlates with interleukin-1b and interleukin-6 but not iron deficiency in children with Helicobacter pylori infection The Korean Journal of Internal Medicine Vol. 25, No. 2, June 2010; р. 195–200
  74. Emiralioglu N, Yenicesu I, Sari S, Egritas O, Poyraz A, Pasaoglu OT, et al. An insight into the relationships between prohepcidin, iron deficiency anemia, and interleukin-6 values in pediatric Helicobacter pylori gastritis. Eur J Pediatr 2015;174:903e10.
  75. Choe YH, Oh YJ, Lee NG, Imoto I, Adachi Y, Toyoda N, Gabazza EC. Lactoferrin sequestration and its contribution to iron-deficiency anemia in Helicobacter pylori-infected gastric mucosa. J Gastroenterol Hepatol 2003; 18:980–5; http://dx.doi. org/10.1046/j.1440–1746.2003.03098.x

Full text is published :
Shulyat’eva N.V., Drozdov V. N., Serebrova S. Yu., Starodubcev A. K., Shih E. V. THE VALUE OF THE H. PYLORI INFECTION IN THE DEVELOPMENT OF IRON DEFICIENCY. Experimental and Clinical Gastroenterology Journal. 2018;154(06):105-110
Read & Download full text

1. Institute of advanced training of the Federal medical and biological Agency of Russia» (Moscow, Russian Federation)
2. MSMSU them. A. I. Evdokimov (Moscow, Russian Federation)
3. Lyubertsy Kozhno-Venerologicheskiy Dispanser (Lyubertsy, Russian Federation)

Keywords: rosacea, Helicobacter pylori, proton pump inhibitors

Abstract:The available numerous literature data indicate that Helicobacter pylori infection (HP) plays an important role in the etiology and pathogenesis of diseases that are not related to the digestive system (atherosclerosis, diabetes, thrombocytopenic purpura, Sjogren’s disease), including skin diseases (chronic urticaria, atopic dermatitis, itching, psoriasis, red flat lichen, focal alopecia, rosacea, etc.). The role of Helicobacter pylori infection during these diseases is described in detail and the need for eradication therapy is proved. The importance of studying gastrointestinal lesions in patients with this pathology for the purpose of complex pathogenetic therapy is confirmed.

• References total 33 ⇓ :: .
  1. Rainer BM, Fischer AH, Luz Felipe da Silva D, Kang S, Chien AL. Rosacea is associated with chronic systemic diseases in a skin severity-dependent manner: results of a case-control study. J Am Acad Dermatol. 2015;73:604–608.
  2. Hua TC, Chung PI, Chen YJ, et al. Cardiovascular comorbidities in patients with rosacea: a nationwide case-control study from Taiwan. J Am Acad Dermatol. 2015;73:249–254.
  3. Egeberg A, Hansen PR, Gislason GH, Thyssen JP. Clustering of autoimmune diseases in patients with rosacea. J Am Acad Dermatol. 2016;74:667–672.
  4. Egeberg A, Hansen PR, Gislason GH, Thyssen JP. Association of rosacea with risk for glioma in a Danish nationwide cohort study. JAMA Dermatol. 2016;152:541–545.
  5. Potekayev N. N. Rosacea (etiology, clinic, therapy) Moscow, Binom Publ., 2000. 20 p.
  6. Egeberg, A. Rosacea and gastrointestinal disorders: a population-based cohort study /A. Egeberg, L. B. Weinstock, E. P. Thyssen, G. H. Gislason, J. P. Thyssen // Br. J. Dermatol. – 2017. – Vol. 176. – № 1. – P. 100–106.
  7. Perlamutrov YU.N. Comparative evaluation of the effectiveness of various methods of treatment of rosacea / YU.N. Perlamutrov, V.SH. Sajdalieva, K. B. Ol’hovskaya. journal of dermatology and venereology. 2011. no.3. pp. 73–79.
  8. Vemuri, R. C. Major pathophysiological correlations of rosacea: a complete clinical appraisal / R. C. Vemuri, R. Gundamaraju, S. D. Sekaran, R. Manikam // Int. J. Med. Sci. – 2015. – Vol. 12. – № 5. – P. 387–396.
  9. Lynn DD, Umari T, Dunnick CA, Dellavalle RP. The epidemiology of acne vulgaris in late adolescence. Adolescent Health, Medicine and Therapeutics. 2016;7:13–25.
  10. Tan J., Berg M. Rosacea: current state of epidemiology. J Am Acad Dermatol. 2013: 69: S27—S35.
  11. Tan J, Schöfer H, Araviiskaia E, et al. Prevalence of rosacea in the general population of Germany and Russia – The RISE study. Journal of the European Academy of Dermatology and Venereology. 2016;30(3):428–434.
  12. Fitzpatrick, T. B. (1975). “Soleil et peau” [Sun and skin]. Journal de Médecine Esthétique (in French) (2): 33–34 Chang AL, Raber I, Xu J, Li R, Spitale R, Chen J, Kiefer AK, Tian C, Eriksson NK, Hinds DA, Tung JY. Assessment of the genetic basis of rosacea by genome-wide association study. J Invest Dermatol. 2015 Jun;135(6): 1548–1555. https://doi.org/ 10.1038/jid.2015.53
  13. Chang AL, Raber I, Xu J, Li R, Spitale R, Chen J, Kiefer AK, Tian C, Eriksson NK, Hinds DA, Tung JY. Assessment of the genetic basis of rosacea by genome-wide association study. J Invest Dermatol. 2015 Jun;135(6): 1548–1555. https://doi.org/ 10.1038/jid.2015.53
  14. Aldrich N, Gerstenblith M, Fu P, Tuttle MS, Varma P, Gotow E, Cooper KD, Mann M, Popkin DL. Genetic vs environmental factors that correlate with rosacea: a cohort-based survey of twins. JAMA Dermatol. 2015 Nov; 151(11):1213–1219. https://doi.org/10.1001/jamadermatol.2015.2230
  15. Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R, Powell F. Standard classification of rosacea: report of the national rosacea society expert committee on the classification and staging of rosacea. J Am Acad Dermatol. 2002 Apr;46(4):584–587.
  16. Yamasaki K, Di Nardo A, Bardan A, Murakami M, Ohtake T, Coda A, Dorschner RA, Bonnart C, Descargues P, Hovnanian A, Morhenn VB, Gallo RL. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13(8):975–80.
  17. Two AM, Del Rosso JQ. Kallikrein 5-mediated inflammation in rosacea: clinically relevant correlations with acute and chronic manifestations in rosacea and how individual treatments may provide therapeutic benefit. J Clin Aesthet Dermatol. 2014;7(1):20–5.
  18. Coda AB, Hata T, Miller J, Audish D, Kotol P, Two A, Shafiq F, Yamasaki K, Harper JC, Del Rosso JQ, Gallo RL. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. J Am Acad Dermatol. 2013;69(4):570–7.
  19. Muto Y, Wang Z, Vanderberghe M, Two A, Gallo RL, Di Nardo A. Mast cells are key mediators of cathelicidin-initiated skin inflammation in rosacea. J Invest Dermatol. 2014;134(11):2728–36.
  20. Koczulla R, von Degenfeld G, Kupatt C, Krötz F, Zahler S, Gloe T, Issbrücker K, Unterberger P, Zaiou M, Lebherz C, Karl A, Raake P, Pfosser A, Boekstegers P, Welsch U, Hiemstra PS, Vogelmeier C, Gallo RL, Clauss M, Bals R. An angiogenic role for the human peptide antibiotic LL-37 /hCAP-18. J Clin Invest. 2003;111(11):1665–72.
  21. Egeberg A, Hansen PR, Gislason GH, Thyssen JP. Clustering of autoimmune diseases in patients with rosacea. J Am Acad Dermatol. 2016 Apr;74(4):667–72.e1. doi: 10.1016/j.jaad.2015.11.004.
  22. Spoendlin J, Karatas G, Furlano RI, Jick SS, Meier CR. Rosacea in Patients with Ulcerative Colitis and Crohn’s Disease: A Population-based Case-control Study. Inflamm Bowel Dis. 2016 Mar;22(3):680–7. doi:10.1097/MIB.0000000000000644.
  23. Egeberg A, Weinstock LB, Thyssen EP, Gislason GH, Thyssen JP. Rosacea and gastrointestinal disorders: a population-based cohort study. Br J Dermatol. 2017 Jan;176(1):100–106. doi: 10.1111/bjd.14930
  24. CHernyak A.YA., Rusak YU.EH., Berger V. V. EHndoskopicheskaya kartina porazhenij zheludka u bol’nyh rozacea, associirovannyh s Helicobacter pylori. Tezisy nauchnyh rabot YII Vserossijskogo s”ezda, ch. I «Dermatologiya», Moskva, 2001. – S.202
  25. Slesarenko N. A., Leonova M. A., Bakulev A. L., Davydova A. V., Slesarenko N. S., Katkova I. O. The role of Helicobacter pylori as a trigger factor in the development of rosacea and the effect of its eradication on the course of dermatosis. Bulletin of dermatology and venereology. 2012. no. 2. pp. 33–39.
  26. Samsonov A. A. proton pump Inhibitors-drugs of choice in the treatment of acid-dependent diseases. Pharmateca. 2007. No. 6. p. 10–15
  27. Minushkin O. N., Maslovskij L. V., Evsikov A. E., SHaposhnikova O. F., Makarova M. S. The effectiveness of injection and oral applications of proton pump inhibitor in the treatment of pancreatitis. Doktor.Ru Gastroenterology. 2015;103(2):19–24
  28. Sachs G. et al. Synthesis or rupture: duration of acid inhibition by proton pump inhibitors // Drugs Today. 2003. Vol. 39. Suppl. A.P. S11–14
  29. Uspenskij YU. P. 1, Pahomova I. G. The choice of proton pump inhibitors in polymorbid patients. Experimental and clinical gastroenterology, 2013, no. 2, pp. 65–71
  30. Mahov V. M., Turko T. V., Volodina T. V., Kulesh I. A. Proton pump inhibitors-the main link in the treatment of acid-dependent pathology// Russian medical journal. Gastroenterology. – 2013. – № 13. P. 698–701
  31. Masharova A. A., Bordin D. S., Kozhurina T.S, YAnova O.B., Kim V. A., Zelenikin S. A. Preimushchestva pantoprazola v terapii gastroehzofageal’noj reflyuksnoj bolezni. Lechashchij vrach, № 7, 2010. S.78
  32. Masharova A. A., YAnova O.B., Valitova EH.R., Kim V. A., Zelenikin S. A. The effectiveness of the drug Panum (pantoprazole) in the treatment of patients with GERD. Experimental and clinical gastroenterology. 2011. No. 4. P. 81–85
  33. Golofeevskij V.YU. Otkrytoe prospektivnoe issledovanie po principu «sluchaj-kontrol’». Zaklyuchenie o terapevticheskoj ehkvivalentnosti preparata «PANUM®». «Gastroehnterologiya Sankt-Peterburga», 2016, № 1–2, s. M8

Full text is published :
Matushevskaya E. V., Komissarenko I. A., Matushevskaya Yu.I. THE ROLE OF HELICOBACTER PYLORI IN THE PATHOGENESIS OF ROSACEA. TREATMENT WITH PROTON PUMP INHIBITORS. Experimental and Clinical Gastroenterology Journal. 2018;154(06):111-115
Read & Download full text